
|Videos|August 8, 2018
Dr. Ai on the FDA Approval of Mogamulizumab in CTCL
Author(s)Wei Z. Ai, MD
Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Advertisement
Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Decisions to Look For in 1H 2026
2
Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401
3
Integrating AI Tools Into Clinical Practice for Genetic Counselors
4
Pillars of Progress: Top News in Oncology From 2025
5































